MSN Labs gets USFDA nod for generic version of Cangrelor in India
Hyderabad: Close on the heels of securing Drug Controller General of India's approval for CANREAL injection (generic version of Cangrelor) in India, MSN Laboratories has received tentative approval for the said injection from US Food and Drug Administration (USFDA).
Cangrelor is used in patients undergoing coronary angioplasty to reduce risk of heart attack and blood clots.
MSN Group commented: "Besides reflecting the capability of MSN Laboratories to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US."
It will be manufactured at a FDA and MHRA approved state-of-the-art injectable facility in Hyderabad.
Read also: MSN Labs launches renal cancer treatment Cabolong
Founded in 2003, MSN Group is the research-based pharmaceutical companies based out of Hyderabad, India. The organization presently has 16 state-of-the-art manufacturing facilities (twelve API and four finished dosage facilities) established across India and USA. The Group has an integrated R&D center for both API and formulation under one roof.
Read also: MSN Labs, DRDE ink pact for COVID drug 2-DG
